Companies › Viatris
3 active drug programs in 18 registered trials: 6 Phase 4, 5 Phase 1, 4 Phase 2, 3 Phase 3; Ophthalmology, Neurology, Infectious disease, Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Gabapentin Voltage-gated calcium channel modulator | Ion channels, CACNB4, CACNB2, CACNB1, CACNB3 | Phase 4 | Healthy; Tonsillitis; Dental Pain and Sensation Disorder; Pain, Postoperative … | Jan 2027 |
| Fluticasone Propionate Glucocorticoid receptor agonist | NR3C1 | Phase 4 | Allergic Rhinitis Due to Allergens | – |
| MR-146 Gene therapy for neurotrophic keratopathy | – | Phase 1 | Neurotrophic Keratopathy | Nov 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03625011 | Gabapentin | Phase 4 | Tonsillitis | Respiratory | Dec 2019 |
| NCT03825809 | Gabapentin | Phase 2 | Narcotic Use | Other | Jan 2020 |
| NCT06752486 | Gabapentin | Phase 1 | Pain After Photorefractive Keratectomy | Ophthalmology | May 2025 |
| NCT05921604 | Gabapentin | Phase 3 | Post Operative Pain | Other | Aug 2025 |
| NCT07597473 | Fluticasone Propionate | Phase 4 | Allergic Rhinitis Due to Allergens | Immunology | Sep 2026 |
| NCT04860141 | Gabapentin | Phase 4 | Dental Pain and Sensation Disorder | Other | Dec 2026 |
| NCT05664464 | Gabapentin | Phase 1 | Glioblastoma | Oncology | Dec 2026 |
| NCT05156060 | Gabapentin | Phase 1 | Head and Neck Cancer | Oncology | Dec 2026 |
| NCT06379425 | Gabapentin | Phase 4 | Pain, Postoperative | Neurology | Jan 2027 |
| NCT07813026 | Gabapentin | Phase 4 | Healthy | Other | Jan 2027 |
| NCT07916116 | Gabapentin | Phase 2 | Postdural Puncture Headache (PDPH) | Neurology | Mar 2027 |
| NCT05443555 | Gabapentin | Phase 2 | HIV | Infectious disease | Jun 2027 |
| NCT07923045 | MR-146 | Phase 1 | Neurotrophic Keratopathy | Ophthalmology | Nov 2027 |
| NCT07308717 | Gabapentin | Phase 4 | Breast Cancer | Oncology | Dec 2027 |
| NCT03498261 | Gabapentin | Phase 1 | Pain, Postoperative | Psychiatry | Dec 2027 |
| NCT04724252 | Gabapentin | Phase 2 | Pain, Postoperative | Other | Dec 2027 |
| NCT05827159 | Gabapentin | Phase 3 | Alcohol Use Disorder | Psychiatry | Aug 2028 |
| NCT06992427 | Gabapentin | Phase 3 | Head and Neck Squamous Cell Carcinoma | Oncology | Aug 2029 |
Cash of $1.8bn on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.